FDA Rejects Reproxalap: Second Complete Response Letter Issued

The U.S. Food and Drug Administration (FDA) has issued a second Complete Response Letter (CRL) for reproxalap, an investigational treatment for dry eye disease, developed by Aldeyra Therapeutics. This marks a significant setback for the company and for individuals seeking recent therapeutic options for this common condition. The FDA’s concerns center on a lack of conclusive evidence demonstrating the drug’s effectiveness in adequately controlled clinical trials.

Understanding Complete Response Letters

A Complete Response Letter isn’t a rejection, but it’s not an approval either. It indicates that the FDA requires further information or clarification before it can approve a new drug for market. The agency’s primary concern, as outlined in the CRL, is that the available data doesn’t provide “substantial evidence” that reproxalap works as intended for the treatment of dry eye disease. Specifically, the FDA cited “inconsistency of study results” and stated that “the totality of evidence…does not support the effectiveness of the product.” This means the clinical trial data presented didn’t convincingly demonstrate a benefit that outweighed potential risks, or that the results were too variable to be reliable.

Dry eye disease affects millions of people, causing discomfort, vision problems, and reduced quality of life. Current treatments range from artificial tears to prescription medications, but many patients don’t find sufficient relief. Reproxalap represents a novel approach, aiming to address the underlying inflammatory processes involved in dry eye.

A History of Regulatory Hurdles

This isn’t the first time reproxalap has faced FDA scrutiny. Aldeyra previously received CRLs in November 2023 and April 2025 for the same New Drug Application (NDA). Ophthalmology Times reports that this is now the third such letter. The repeated requests for additional information suggest the FDA has significant reservations about the drug’s profile.

What the FDA Found – and Didn’t Find

Importantly, the FDA’s latest CRL, and those preceding it, did not raise concerns about the safety of reproxalap or the manufacturing process. This suggests the drug itself appears to be safe to produce and administer. The core issue remains efficacy – whether it actually works as claimed. The FDA specifically noted that the inconsistencies across different trials raised doubts about the reliability of any positive findings.

According to a press release from Aldeyra, the FDA provided draft label language in December 2025 and again in March 2026, indicating a willingness to operate towards approval if the efficacy concerns could be addressed. However, the company states that label negotiations were not completed.

What Does This Mean for Patients?

For individuals living with dry eye disease, this news is likely disappointing. It means a potentially new treatment option is not currently available. However, it’s crucial to understand that this doesn’t necessarily mean reproxalap will never be approved. It simply means Aldeyra needs to address the FDA’s concerns with further data or analysis. Patients should continue to work with their eye care professionals to manage their symptoms using currently available treatments.

Aldeyra’s Response and Future Steps

Aldeyra Therapeutics doesn’t currently plan to conduct additional clinical trials. Instead, the company intends to request a Type A meeting with the FDA – a formal discussion to clarify the specific steps needed for NDA approval. The FDA has recommended exploring the reasons for failures in certain trials and identifying specific patient populations or conditions where reproxalap might be effective. This suggests the FDA isn’t closing the door entirely, but wants to see a more focused approach to demonstrating the drug’s benefit.

The FDA’s recommendation to explore specific populations is a common strategy in drug development. Sometimes a drug doesn’t work for everyone, but it may be highly effective for a subset of patients with specific characteristics. Identifying those patients could be key to eventual approval.

The Regulatory Landscape for Dry Eye Treatments

The development of new treatments for dry eye disease is an active area of research. The FDA’s rigorous review process is designed to ensure that only safe and effective medications reach patients. AJMC highlights the challenges faced by Aldeyra, emphasizing the high bar for demonstrating efficacy in clinical trials. The agency’s scrutiny reflects the importance of ensuring that new treatments offer a genuine benefit to patients.

The FDA’s decision underscores the complexities of clinical trial design and data interpretation. Demonstrating efficacy requires not only showing that a drug has a positive effect, but also that the effect is statistically significant, clinically meaningful, and consistent across different studies.

What comes next will depend on the outcome of Aldeyra’s meeting with the FDA and the company’s subsequent actions. The situation remains fluid, and further updates will be crucial for both the company and the patients who are hoping for new treatment options for dry eye disease.